ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2021
Dual Size/Charge-Switchable Nanocatalytic Medicine for Deep Tumor Therapy.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 93 citations in OpenAlex.
- Driving Drugs Deeper: Force-Driven Microneedle Systems for Active Therapy and Their Road Towards Clinical Implementation.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Advances in Nanoarchitectural Designs for Anticancer Drug Delivery to Deep Tumors.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- A Hydrogen-Releasing Nanozyme Engineers a Mitochondrial ROS Amplifier for Self-Sustaining Catalytic Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Two-dimensional nanomaterials for bone disease therapy: multifunctional platforms for regeneration, anti-infection and tumor ablation.Journal of nanobiotechnology · 2025Review
- Stealth missiles with precision guidance: A novel multifunctional nano-drug delivery system based on biomimetic cell membrane coating technology.Materials today. Bio · 2025Review
- Article
- Ultrasound-triggered nano delivery of lenvatinib for selective immunotherapy treatment against hepatocellular carcinoma.Scientific reports · 2024Article
- Ultrasound-triggered and glycosylation inhibition-enhanced tumor piezocatalytic immunotherapy.Nature communications · 2024Article
- A TME-enlightened protein-binding photodynamic nanoinhibitor for highly effective oncology treatment.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Bacteria-driven nanosonosensitizer delivery system for enhanced breast cancer treatment through sonodynamic therapy-induced immunogenic cell death.Journal of nanobiotechnology · 2024Article
- Review
- Ultrasound technology assisted colloidal nanocrystal synthesis and biomedical applications.Ultrasonics sonochemistry · 2024Review
- Application of Carbon Nanomaterials to Enhancing Tumor Immunotherapy: Current Advances and Prospects.International journal of nanomedicine · 2024Review
- Recent progress of metal-based nanomaterials with anti-tumor biological effects for enhanced cancer therapy.Exploration (Beijing, China) · 2023Review
- Copper-mediated chemodynamic therapy with ultra-low copper consumption by doping cupric ion on cross-linked (Regenerative biomaterials · 2023Article
- Bacterial Metabolism-Initiated Nanocatalytic Tumor Immunotherapy.Nano-micro letters · 2022Article
- A platinum-ruthenium hybrid prodrug with multi-enzymatic activities for chemo-catalytic therapy of hypoxic tumors.Chemical science · 2022Article
- Novel Strategy for Optimized Nanocatalytic Tumor Therapy: From an Updated View.Small science · 2022Article
- Oxidative Stress in Cancer Immunotherapy: Molecular Mechanisms and Potential Applications.Antioxidants (Basel, Switzerland) · 2022Review
- Stimuli-Responsive Nanoparticles for Controlled Drug Delivery in Synergistic Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Elevating intratumoral levels of highly toxic reactive oxygen species (ROS) by nanocatalytic medicine for tumor-specific therapy without using conventional toxic chemodrugs is recently of considerable interest, which, however, still suffers from less satisfactory therapeutic efficacy due to the relatively poor accumulation at the tumor site and largely blocked intratumoral infiltration of nanomedicines. Herein, an ultrasound (US)-triggered dual size/charge-switchable nanocatalytic medicine, designated as Cu-LDH/HMME@Lips, is constructed for deep solid tumor therapy via catalytic ROS generations. The negatively charged liposome outer-layer of the nanomedicine enables much-prolonged blood circulation for significantly enhanced tumoral accumulation, while the positively charged Fenton-like catalyst Cu-LDH released from the liposome under the US stimulation demonstrates much enhanced intratumoral penetration via transcytosis. In the meantime, the co-released sonosensitizer hematoporphyrin monomethyl ether (HMME) catalyze the singlet oxygen (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.